Pharmacogenomics: The promise of personalized medicine

AAPS Journal

Volumn 2, Issue 1, 2000, Pages

  Mancinelli, Laviero ^a   Cronin, Maureen ^a   Sadée, Wolfgang ^b  

^a ACLARA BioSciences Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pharmacogenomics

Indexed keywords

EID: 52849102827     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200-1205.
2. Sadee W. Finding the right drug for the right patient. Pharm Res. 1998;15:959-963.
3. Maynard Smith J. The Theory of Evolution. Baltimore, Maryland: Penguin Books; 1962.
4. Garrod AE. The incidence of alcaptonuria: a study in chemical individuality. Lancet. 1902;ii:1616-1620.
5. Snyder LH. Studies in human inheritance. Ohio J Sci. 1932;32:436-468.
6. Ford EB. Genetic Polymorphism. London: Faber & Faber; 1965.
7. Nebert DW. Pharmacogenetics: 65 candles on the cake. Pharmacogenetics. 1997;7:435-440.
8. Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: W. B. Saunders; 1962.
9. Carsen PE, Flanagan CL, Iokes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124,484-485.
10. Hughes HB, Biehl JP, Jones AP, Schmidt, LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberculosis. 1954;70:266-273.
11. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2:485-490.
12. Vatsis K, Martell KJ, Weber WW. Proc Natl Acad Sci U S A. 1991;88:6333.
13. Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA. 1957;165:835-837.
14. Eichelbaum M, Steincke B, Dengler JJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1977;16:183-187.
15. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-62.
16. Tai H, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58:694-702.
17. Goldenberg MM. Trastuzumab, a recombinant DNA derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Therapeut. 1999;21:309-318.
18. Baselge J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (HERCEPTIN) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825-2831.
19. Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P450 enzymes. Drug Metab Drug Interact. 1997;14:55-82.
20. Evans DAP. Genetic factors in drug therapy. In: Clinical and Molecular Pharmacogenetics. Cambridge: Cambridge University Press; 1993.
21. Buchert E, Woosley RL. Clinical implications of variable antiarrythmic drug metabolism. Pharmacogenet. 1992;2:2-11.
22. Dahl AK, Bertilsson, L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenet. 1993;3:61-70.
23. Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther. 1999;24:7-16
24. de Morais S, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994,269:15419-15422.
25. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med. 1995;73:39-553.
26. Gonzales FJ. Pharmacogenetic phenytyping and genotyping. Present status and future potential. Clin Pharmacokinet. 1994;26:59-70.
27. Ball SE, Scatina JA, Sisenwine SF, Fisher GL. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem Toxicity. 1995;18:1-28.
28. Guengerich F. The Environmental Genome Project: Functional analysis of polymorphisms. Environment Health Perspect. 1998;106:365-368.
29. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998;281:1820-1821.
30. Sadee W. Pharmacogenomics. BMJ. 1999;319:1286.
31. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
32. Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts to serum. Science. 1999;283,83-87.
33. Schachter B. Pharming the Genome. Biomednet [serial onlineJ. October 30, 1998;41.
34. Fluri KG, Fitzpatrick G, Chiem N, Harrison DJ. Integrated capillary electrophoresis devices with an efficient postcolumn reactor in planar quartz and glass chips. Anal Chem. 1996;68:4285-4290.
35. Jacobson SC, Ramsey SC. Integrated microdevice for DNA restriction fragment analysis. Anal Chem. 1996;68:720-723.
36. Blanchard AP, Friend SH. Cheap DNA arrays-;it's not all smoke and mirrors. Nature Biotech. 1999;17:953.
37. Russo E. Big pharma hedges its bets. The Scientist. 1999;13:1.
38. Poste G. In Bio '98 International Meeting and Exposition 1-9. New York: RAND Corporation; 1999.
39. Weber WW. Pharmacogenetics. New York: Oxford University Press; 1997.